Humanwell Healthcare Group Co Ltd (600079.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE000000QW6
Humanwell Healthcare Group Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 25.44 bn CNY | 23.96 bn CNY |
| Gross profit | 11.31 bn CNY | 11.55 bn CNY |
| Operating income | 2.52 bn CNY | 3.82 bn CNY |
| EBIT | 3.01 bn CNY | 3.33 bn CNY |
| Net income | 1.33 bn CNY | 1.86 bn CNY |
| Diluted EPS – continuing operations | 0.82 CNY | 1.14 CNY |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds; compound muniziqi granules to treat skin and gynecologicalconditions; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals. In addition, the company offers progesterone, estrogen, androgen, cortical hormone, and other API products; steroid hormone products; natural plant-based medicines; central nervous system drugs; animal medicine; narcotics; and Uyghur medicine products. Further, it is involved in the production of veterinary drugs, feed additive, medical devices, and agricultural products; technical development, exchange, and transfer; leasing of medical devices; conference, exhibition, inspection, and testing; property management; pharmaceutical contract manufacturing; cleaning, washing, and disinfection; warehousing and logistics; investment management and consulting services; and production of health foods. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1988 and is based in Wuhan, China.
More stocks
- Amada Co Ltd (6113.T)
- Acushnet Holdings Corp. (GOLF)
- Charoen Pokphand Foods Public Company Limited (CPF.BK)
- Sonae SGPS SA (SON.LS)
- Karman Holdings Inc. (KRMN)
- Netskope Inc (NTSK)
- Far Eastern New Century Corp (1402.TW)
- Guangzhou Shiyuan Electronic Technology Co Ltd (002841.SZ)
- Beijing Yanjing Brewery Co Ltd (000729.SZ)
- Yifeng Pharmacy (603939.SS)
- Chipbond Technology (6147.TWO)
- Yuhan Corp. (000100.KS)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.